Evidence map›Paper›PMID 40851498›Full record

ArticleJournal of natural products2025

Identification of Cembrane Diterpenoids from

Maria Orfanoudaki, Anam F Shaikh, Dongdong Wang, Vivek Singh, Lin Du, Jennifer A Wilson, Antony Wamiru, Ekaterina I Goncharova, Nathanael Pruett, Chuong D Hoang and 2 more

Abstract read
In one paragraph

Article in Journal of natural products, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maria OrfanoudakiMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.ORCID 0000-0002-9409-7645
Anam F ShaikhMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.
Dongdong WangMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.ORCID 0000-0002-7824-2507
Vivek SinghThoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.
Lin DuMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.ORCID 0000-0001-8751-4482
Jennifer A WilsonMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.
Antony WamiruMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.
Ekaterina I GoncharovaMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.
Nathanael PruettThoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.
Chuong D HoangThoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.
Brice A P WilsonMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.ORCID 0000-0001-8988-1964
Barry R O'KeefeThoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.ORCID 0000-0003-0772-4856

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
microRNA regulatory networks in thoracic cancersZIABC011657 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HOANG, CHUONG · 2015 to 2025
$18.1M
Assay development and screening for molecular targets and discoveryZIABC011904 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, BRICE · 2019 to 2025
$12.8M
Cell-free assay technologies for the identification of active compoundsZIABC011471 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OKEEFE, BARRY · 2012 to 2025
$12.4M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC011471Intramural NIH HHS ZIA BC011657Intramural NIH HHS ZIA BC011904NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Diffuse pleural mesothelioma (DPM) is a rare but aggressive late-onset cancer. A high-throughput screen of a natural product fraction library identified fractions derived from an aqueous extract of

Indexed as

AnthozoaAntineoplastic AgentsDiterpenesMesotheliomaAnimalsCell Line, TumorCell SurvivalDrug Screening Assays, AntitumorHumansMesothelioma, MalignantMolecular StructurePleural NeoplasmsAntineoplastic AgentscembraneDiterpenes

Identifiers

PMID40851498
PMCPMC12481565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.